Atsena Therapeutics, announced that the FDA has granted Orphan Drug Designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). According to the company, ATSN-201, a gene therapy product candidate, leverages AAV.SPR, Atsena’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment. Read More: https://ow.ly/xOli50Tppno
